Header Logo

HELEN HESLOP

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleDirector
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Medicine
    DivisionMedicine-Hematology & Oncology


    Collapse Biography 
    Collapse awards and honors
    2021Elected, National Academy of Medicine
    2004Elected, Association of American Physicians

    Collapse Research 
    Collapse research activities and funding
    R13TR002411     (HESLOP, HELEN E)Feb 15, 2018 - Jan 31, 2021
    NIH
    American Society of Gene & Cell Therapy (ASGCT) 21st Annual Meeting
    Role: Principal Investigator
    R13TR002018     (HESLOP, HELEN E)May 1, 2017 - Apr 30, 2018
    NIH
    American Society of Gene & Cell Therapy (ASGCT) 20th Annual Meeting
    Role: Principal Investigator
    UG1HL108945     (BOLLARD, CATHERINE M.;HESLOP, HELEN E)Aug 8, 2011 - Jun 30, 2024
    NIH
    Targeting HIV and EBV Antigens in Patients with HIV Lymphoma
    Role: Principal Investigator
    U10HL108945     (HESLOP, HELEN E)Aug 8, 2011 - Jun 30, 2017
    NIH
    Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
    Role: Principal Investigator
    P30CA125123     (HESLOP, HELEN E)Jul 1, 2007 - Jun 30, 2025
    NIH
    Baylor College of Medicine Cancer Center-Cancer Center Support Grant
    Role: Co-Principal Investigator
    P50CA126752     (BRENNER, MALCOLM K.;HESLOP, HELEN E)Apr 1, 2007 - Aug 31, 2027
    NIH
    SPORE in Lymphoma
    Role: Principal Investigator
    T32HL092332     (HESLOP, HELEN E)Jul 1, 2003 - Jul 31, 2023
    NIH
    Training In Cell and Gene Therapy
    Role: Principal Investigator
    T32DK064717     (HESLOP, HELEN E)Jul 1, 2003 - Dec 31, 2008
    NIH
    Training in Cell and Gene Therapy
    Role: Principal Investigator
    P01CA094237     (HESLOP, HELEN E)Dec 1, 2001 - Jan 31, 2020
    NIH
    ENHANCING T CELL THERAPY OF CANCER
    Role: Principal Investigator
    R01HL055703     (HESLOP, HELEN E)Sep 30, 1995 - Aug 31, 1999
    NIH
    DOUBLE GENE MARKING TO ANALYZE STEM CELLS IN CHILDREN
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hill LC, Rouce RH, Wu M, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla PD, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin M, Hill LC, Rouce RH, Wu MJ, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla P, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin M. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241. PMID: 38145560; PMCID: PMC10997912.
      Citations:    Fields:    Translation:HumansCells
    2. Mo F, Tsai CT, Zheng R, Cheng C, Heslop HE, Brenner MK, Mamonkin M, Watanabe N. Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Mar 12. PMID: 38506769.
      Citations:    Fields:    
    3. Heslop HE. Long-Term Follow-Up for Recipients of Genetically Modified Cells: A Team Effort. Transplant Cell Ther. 2024 Mar; 30(3):247-249. PMID: 38485335.
      Citations:    Fields:    
    4. Curran KJ, Nikiforow S, Bachier C, Hsu YM, Maloney DG, Maus MV, McCarthy PL, Porter DL, Shi PA, Shpall EJ, William B, Wacker K, Warkentin P, Heslop HE, Curran KJ, Nikiforow S, Bachier C, Hsu YM, Maloney D, Maus MV, McCarthy P, Porter D, Shi P, Shpall EJ, William B, Wacker K, Warkentin P, Heslop HE. A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help. Blood Adv. 2024 Feb 27; 8(4):1053-1061. PMID: 37467016; PMCID: PMC10920101.
      Citations:    Fields:    Translation:HumansCells
    5. Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 Feb; 30(2):338-341. PMID: 38195751.
      Citations: 2     Fields:    Translation:Humans
    6. Kapadia CD, Rosas G, Thakkar SG, Wu M, Torrano V, Wang T, Grilley BJ, Heslop HE, Ramos CA, Goodell MA, Lulla PD. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy. Cytotherapy. 2024 Mar; 26(3):261-265. PMID: 38149948; PMCID: PMC10922117.
      Citations:    Fields:    Translation:Humans
    7. Llaurador G, Shaver K, Wu M, Wang T, Gillispie A, Doherty E, Craddock J, Read J, Yassine K, Morales E, George A, Steffin D, Krance R, Martinez C, Heslop H, Salem B, Llaurador G, Shaver K, Wu M, Wang T, Gillispie A, Doherty E, Craddock J, Read J, Yassine K, Morales E, George A, Steffin D, Krance R, Martinez C, Heslop H, Salem B. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 Feb; 30(2):217-227. PMID: 37931800.
      Citations:    Fields:    Translation:Humans
    8. Llaurador GA, Heslop HE, Steffin DH. Moving CAR-Ts to the outpatient clinic. Br J Haematol. 2023 11; 203(4):507-508. PMID: 37751752.
      Citations:    Fields:    Translation:HumansCells
    9. Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla P. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850. PMID: 36373249; PMCID: PMC10316279.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    10. Heslop HE. Introduction to a How I Treat series on emergent CAR T-cell toxicities. Blood. 2023 05 18; 141(20):2405-2407. PMID: 36928098.
      Citations:    Fields:    Translation:HumansCells
    11. Martinez C, Aguayo-Hiraldo P, Chaimowitz N, Forbes L, Rider N, Nicholas S, Seeborg F, Chinen J, Chinn I, Davis C, Roseblatt H, Noroski L, Omer B, John T, Yassine K, Naik S, Craddock J, Bhar S, Allen C, Ahmed N, Sasa G, Steffin D, Doherty E, George A, Salem B, Friend B, Hegde M, Brenner MK, Heslop HE, Leen A, Pe?a A, Wu M, Hanson IC, Krance RA. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830. PMID: 36453638; PMCID: PMC10165184.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    12. Sharma S, Woods M, Mehta NU, Sauer T, Parikh KS, Schmuck-Henneresse M, Zhang H, Mehta B, Brenner MK, Heslop HE, Rooney CM. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4). PMID: 37072346; PMCID: PMC10124261.
      Citations:    Fields:    Translation:HumansAnimalsCells
    13. Wang D, Porter CE, Lim B, Rosewell Shaw A, Robertson CS, Woods ML, Xu Y, Biegert GGW, Morita D, Wang T, Grilley BJ, Heslop H, Brenner MK, Suzuki M. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790. PMID: 36989357; PMCID: PMC10058234.
      Citations:    Fields:    Translation:AnimalsCells
    14. Mo F, Watanabe N, Omdahl KI, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, Brenner MK, Tkachev V, Mamonkin M. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208. PMID: 36044667; PMCID: PMC10023730.
      Citations:    
    15. Heslop HE. Introduction to a review series on banked allogeneic immune effector cells. Blood. 2023 02 23; 141(8):811-812. PMID: 36608323.
      Citations:    Fields:    Translation:Cells
    16. Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Nikiforow S, Locke FL. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies. Transplant Cell Ther. 2023 04; 29(4):228-239. PMID: 36709800.
      Citations:    Fields:    Translation:HumansCells
    17. Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, Lulla P, Krance RA, Scherer L, Ruderfer D, Naik S, Bocchini C, Fraser IP, Patel B, Ward D, Wang T, Heslop HE, Leen AM, Omer B. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330. PMID: 36628536; PMCID: PMC9843433.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    18. Cornetta K, Yao J, House K, Duffy L, Adusumilli PS, Beyer R, Booth C, Brenner M, Curran K, Grilley B, Heslop H, Hinrichs CS, Kaplan RN, Kiem HP, Kochenderfer J, Kohn DB, Mailankody S, Norberg SM, O'Cearbhaill RE, Pappas J, Park J, Ramos C, Ribas A, Rivi?re I, Rosenberg SA, Sauter C, Shah NN, Slovin SF, Thrasher A, Williams DA, Lin TY. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809. PMID: 36518078; PMCID: PMC10014217.
      Citations:    Fields:    Translation:HumansCells
    19. Marinos A, Heslop HE. Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant? Best Pract Res Clin Haematol. 2022 12; 35(4):101414. PMID: 36517124; PMCID: PMC10683866.
      Citations: 1     Fields:    
    20. Bajgain P, Torres Chavez AG, Balasubramanian K, Fleckenstein L, Lulla P, Heslop HE, Vera J, Leen AM. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385. PMID: 36122411; PMCID: PMC9633434.
      Citations:    
    21. Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34. PMID: 36086817; PMCID: PMC9840107.
      Citations:    
    22. Heslop HE. Tumor-intrinsic causes of CAR-T failure. Blood. 2022 08 04; 140(5):414-415. PMID: 35925642; PMCID: PMC9353152.
      Citations:    
    23. Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113. PMID: 35860837; PMCID: PMC9290161.
      Citations:    
    24. Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: 35325065; PMCID: PMC9346960.
      Citations:    Fields:    Translation:HumansCells
    25. Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PD. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711. PMID: 35134127; PMCID: PMC9053698.
      Citations: 1     Fields:    Translation:Humans
    26. Friend BD, Muhsen IN, Patel S, Hill LC, Lulla P, Ramos CA, Pingali SR, Kamble RT, John TD, Salem B, Bhar S, Doherty EE, Craddock J, Sasa G, Wu M, Wang T, Martinez C, Krance RA, Heslop HE, Carrum G. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585. PMID: 35105965.
      Citations:    Fields:    Translation:Humans
    27. John T, Bonifant C, Buchbinder D, Chandra S, Chandrakasan S, Chang W, Chen L, Geerlinks AV, Giller RH, Goyal R, Hagin D, Islam S, Mallhi K, Miller HK, Owen W, Pacheco M, Patel NC, Querfeld C, Quigg T, Richard N, Schiff D, Shereck E, Stenger E, Jordan MB, Heslop HE, Bollard CM, Cohen JI, D?vila Salda?a BJ, Elfassy HL. High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2022 01 25; 6(2):452-459. PMID: 34670275; PMCID: PMC8791566.
      Citations: 1     Fields:    Translation:HumansCells
    28. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368. PMID: 34855460; PMCID: PMC8797487.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    29. Al Hadidi S, Kamble RT, Carrum G, Heslop HE, Ramos CA. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633. PMID: 34461636; PMCID: PMC8759126.
      Citations:    Fields:    Translation:Humans
    30. Leung WK, Ayanambakkam A, Heslop HE, Hill LC. Beyond CD19 CAR-T cells in lymphoma. Curr Opin Immunol. 2022 02; 74:46-52. PMID: 34800921; PMCID: PMC8901457.
      Citations: 1     Fields:    Translation:HumansCells
    31. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 11; 27(11):885-907. PMID: 34461278; PMCID: PMC8556300.
      Citations:    Fields:    Translation:Humans
    32. Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021 Sep; 2(5):408-422. PMID: 34568831; PMCID: PMC8462122.
      Citations: 14     Fields:    Translation:HumansCells
    33. Forbes LR, Eckstein OS, Gulati N, Peckham-Gregory EC, Ozuah NW, Lubega J, El-Mallawany NK, Agrusa JE, Vogel TP, Chaimowitz NS, Rider NL, Mace EM, Orange JS, Caldwell JW, Aldave-Becerra JC, Jolles S, Saettini F, Chong HJ, Stray-Pedersen A, Heslop HE, Kamdar KY, Rouce RH, Muzny DM, Jhangiani SN, Gibbs RA, Coban-Akdemir ZH, Lupski JR, McClain KL, Allen CE, Chinn IK, Poli MC. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766. PMID: 34329649; PMCID: PMC8795244.
      Citations: 1     Fields:    Translation:HumansCells
    34. Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HE, Suarez F. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539. PMID: 34304287.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    35. Al Hadidi S, Dongarwar D, Salihu HM, Kamble RT, Lulla P, Hill LC, Carrum G, Ramos CA, Heslop HE, Usmani SZ. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263. PMID: 34278937; PMCID: PMC8962656.
      Citations: 1     Fields:    Translation:Humans
    36. John TD, Friend B, Yassine K, Sasa G, Bhar S, Salem B, Omer B, Craddock J, Doherty E, Martinez C, Heslop HE, Krance RA, Leung K. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience. Bone Marrow Transplant. 2021 11; 56(11):2797-2803. PMID: 34274957.
      Citations:    Fields:    Translation:Humans
    37. Streck BP, Naufal G, Carrum G, Hill L, Heslop HE, Ramos CA, Kamble R, Cohen M, East K, Sena M, Lulla P. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6. PMID: 34082160.
      Citations:    Fields:    Translation:HumansCells
    38. Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill L, Randhawa J, Gottschalk S, Krance R, Wang T, Wu M, Robertson C, Gee AP, Chung B, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597. PMID: 33270816; PMCID: PMC8120140.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    39. Mo F, Mamonkin M, Brenner MK, Heslop HE. Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272. PMID: 33536140; PMCID: PMC7914205.
      Citations: 5     Fields:    Translation:HumansCells
    40. Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, Bilgi M, Wang T, Wu MJ, Kamble R, Ramos CA, Rouce RH, Zeng Z, Gee AP, Grilley BJ, Vera JF, Bollard CM, Brenner MK, Heslop HE, Rooney CM, Leen AM, Carrum G. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425. PMID: 33507803; PMCID: PMC8274795.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    41. Heslop HE, Sharma S, Rooney CM. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol. 2021 02 10; 39(5):514-524. PMID: 33434061; PMCID: PMC8462582.
      Citations: 1     Fields:    Translation:HumansCells
    42. Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N, Simons BW, McLean Stevens A, Redell MS, Heslop HE, Mamonkin M, Brenner MK, Atilla E. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2). PMID: 32938629; PMCID: PMC7497527.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    43. Lulla PD, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554). PMID: 32727914.
      Citations: 11     Fields:    Translation:Humans
    44. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804. PMID: 32701411; PMCID: PMC7655020.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    45. Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549. PMID: 32669548; PMCID: PMC7363864.
      Citations: 33     Fields:    Translation:HumansCells
    46. Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63. PMID: 32661440; PMCID: PMC7854790.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    47. Heslop HE. Sensitizing Burkitt lymphoma to EBV-CTLs. Blood. 2020 05 21; 135(21):1822-1823. PMID: 32437562; PMCID: PMC7243150.
      Citations: 2     Fields:    Translation:HumansCells
    48. Sharma S, Leung WK, Heslop HE. Virus-specific T cells for malignancies - then, now and where to? Curr Stem Cell Rep. 2020 Jun; 6(2):17-29. PMID: 33738181; PMCID: PMC7963109.
      Citations: 3     
    49. Mo F, Heslop HE, Mamonkin M. CRISPR-Edited Immune Effectors: The End of the Beginning. Mol Ther. 2020 04 08; 28(4):995-996. PMID: 32203679; PMCID: PMC7132620.
      Citations: 2     Fields:    Translation:HumansCells
    50. Levine JE, Antin JH, Allen CE, Burroughs LM, Cooke KR, Devine S, Heslop H, Nakamura R, Talano JA, Yanik G, DiFronzo N. Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2020 05; 26(5):e94-e100. PMID: 32035274; PMCID: PMC8062984.
      Citations: 2     Fields:    Translation:Humans
    51. Naik S, Eckstein O, Sasa G, Heslop HE, Krance RA, Allen C, Martinez C. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87. PMID: 31989587.
      Citations: 6     Fields:    Translation:Humans
    52. Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350. PMID: 31558475; PMCID: PMC7062259.
      Citations: 13     Fields:    Translation:HumansCells
    53. Naik S, Martinez CA, Omer B, Sasa G, Yassine K, Allen CE, Kamdar K, Orth R, Wu M, Leung K, Gottschalk S, Brenner MK, Heslop HE, Krance RA. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695. PMID: 31511228; PMCID: PMC6759733.
      Citations: 2     Fields:    Translation:Humans
    54. Tzannou I, Watanabe A, Naik S, Daum R, Kuvalekar M, Leung KS, Martinez C, Sasa G, Wu M, Gee AP, Krance RA, Gottschalk S, Heslop HE, Omer B. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019 09 10; 3(17):2571-2580. PMID: 31481503; PMCID: PMC6737421.
      Citations: 12     Fields:    Translation:HumansCells
    55. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 12; 25(12):2305-2321. PMID: 31446199.
      Citations: 39     Fields:    
    56. Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145. PMID: 31301099; PMCID: PMC7239317.
      Citations: 5     Fields:    Translation:HumansCells
    57. Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019 10; 187(2):206-218. PMID: 31219185; PMCID: PMC6786907.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    58. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Perales MA, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Hashmi SK, Chabannon C, Hudecek M, Mohty M. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019 11; 54(11):1868-1880. PMID: 31092900; PMCID: PMC8268756.
      Citations: 34     Fields:    
    59. Steffin DHM, Heslop HE. Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. Mol Ther. 2019 05 08; 27(5):900-901. PMID: 31005599; PMCID: PMC6520459.
      Citations: 2     Fields:    Translation:HumansCells
    60. Leung W, Heslop HE. Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR. Cancer Immunol Res. 2019 04; 7(4):528-533. PMID: 30936089; PMCID: PMC6462216.
      Citations: 10     Fields:    Translation:HumansCells
    61. Hill L, Lulla P, Heslop HE. CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm. Adv Cell Gene Ther. 2019 Jul; 2(3). PMID: 31777773; PMCID: PMC6880960.
      Citations: 3     
    62. Heslop HE, Shpall EJ. Harmonizing Immune Effector Toxicity Reporting. Biol Blood Marrow Transplant. 2019 04; 25(4):e121-e122. PMID: 30615980.
      Citations: 2     Fields:    Translation:HumansCells
    63. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Perales MA, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Hashmi SK, Chabannon C, Hudecek M, Mohty M. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 03; 25(3):e76-e85. PMID: 30576834; PMCID: PMC8335749.
      Citations: 36     Fields:    Translation:Humans
    64. McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361. PMID: 30262660; PMCID: PMC6265652.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    65. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737. PMID: 30309819; PMCID: PMC6277484.
      Citations: 77     Fields:    Translation:HumansCells
    66. Nishiyama-Fujita Y, Kawana-Tachikawa AI, Ono T, Tanaka Y, Kato T, Heslop HE, Morio T, Takahashi S. Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy. 2018 09; 20(9):1182-1190. PMID: 30122653.
      Citations: 2     Fields:    Translation:HumansCells
    67. Shum T, Heslop HE. A backpack revs up T-cell activity. Nat Biotechnol. 2018 08 06; 36(8):702-703. PMID: 30080841.
      Citations: 1     Fields:    Translation:HumansCells
    68. Lulla PD, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386. PMID: 29851933; PMCID: PMC6469642.
      Citations: 12     Fields:    Translation:HumansCells
    69. Chinn IK, Eckstein OS, Peckham-Gregory EC, Goldberg BR, Forbes LR, Nicholas SK, Mace EM, Vogel TP, Abhyankar HA, Diaz MI, Heslop HE, Krance RA, Martinez CA, Nguyen TC, Bashir DA, Goldman JR, Pedroza LA, Poli MC, Aldave-Becerra JC, McGhee SA, Al-Herz W, Chamdin A, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Cao TN, Hong DN, Gibbs RA, Lupski JR, Orange JS, McClain KL, Allen CE, Stray-Pedersen A. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100. PMID: 29632024; PMCID: PMC6034641.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    70. Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, Nicholas S, Chinn I, Orange JS, Rider NL, Leung KS, Naik S, Carrum G, Sasa G, Hegde M, Omer BA, Ahmed N, Allen CE, Khaled Y, Wu MF, Liu H, Gottschalk SM, Heslop HE, Brenner MK, Krance RA, Martinez CA. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650. PMID: 29630926.
      Citations: 8     Fields:    Translation:Humans
    71. Yanir AD, Martinez CA, Sasa G, Leung K, Gottschalk S, Omer B, Ahmed N, Hegde M, Eunji J, Liu H, Heslop HE, Brenner MK, Krance RA, Naik S. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431. PMID: 29550628.
      Citations: 8     Fields:    Translation:Humans
    72. Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139. PMID: 29315015; PMCID: PMC5891126.
      Citations: 75     Fields:    Translation:HumansCells
    73. Heslop HE, Brenner MK. Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2. PMID: 29273500; PMCID: PMC5763151.
      Citations: 1     Fields:    Translation:HumansCells
    74. Ngwube A, Hanson IC, Orange J, Rider NL, Seeborg F, Shearer W, Noroski L, Nicholas S, Forbes L, Leung K, Sasa G, Naik S, Hegde M, Omer B, Ahmed N, Allen C, Gottschalk S, Wu MF, Liu H, Brenner M, Heslop H, Krance R, Martinez C. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541. PMID: 29196075.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    75. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471. PMID: 28805662; PMCID: PMC5669573.
      Citations: 140     Fields:    Translation:HumansCellsCTClinical Trials
    76. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557. PMID: 28783452; PMCID: PMC5662844.
      Citations: 135     Fields:    Translation:HumansCellsCTClinical Trials
    77. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101. PMID: 28426845; PMCID: PMC5747970.
      Citations: 269     Fields:    Translation:HumansCellsCTClinical Trials
    78. Rouce RH, Heslop HE. Equal opportunity CAR T cells. Blood. 2017 06 22; 129(25):3275-3277. PMID: 28642356; PMCID: PMC5482104.
      Citations: 2     Fields:    Translation:HumansCells
    79. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224. PMID: 28602436; PMCID: PMC5589058.
      Citations: 168     Fields:    Translation:HumansCells
    80. Mamonkin M, Heslop HE. Exhausting alloreactivity of donor-derived CAR T cells. Nat Med. 2017 02 07; 23(2):147-148. PMID: 28170385.
      Citations: 3     Fields:    Translation:HumansCells
    81. Lulla P, Heslop HE. Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540. PMID: 28153834; PMCID: PMC5290991.
      Citations: 4     Fields:    Translation:HumansCells
    82. Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258. PMID: 28129119; PMCID: PMC5363304.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    83. Lulla P, Heslop HE. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396. PMID: 27913506; PMCID: PMC6142511.
      Citations: 3     Fields:    Translation:HumansCells
    84. Rouce RH, Sharma S, Huynh M, Heslop HE. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017 03; 176(5):688-704. PMID: 27897332; PMCID: PMC5318250.
      Citations: 12     Fields:    Translation:HumansCells
    85. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016; 5(12):e1253656. PMID: 28180032; PMCID: PMC5214260.
      Citations: 78     Fields:    
    86. Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96. PMID: 27270177; PMCID: PMC4922690.
      Citations: 131     Fields:    Translation:HumansCellsCTClinical Trials
    87. Rouce RH, Heslop HE. Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov. 2016 06; 6(6):579-80. PMID: 27261481; PMCID: PMC4894532.
      Citations: 6     Fields:    Translation:HumansCells
    88. Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016 06 30; 127(26):3331-40. PMID: 27207801; PMCID: PMC4929925.
      Citations: 75     Fields:    Translation:HumansAnimalsCells
    89. Kimmelman J, Hyun I, Benvenisty N, Caulfield T, Heslop HE, Murry CE, Sipp D, Studer L, Sugarman J, Daley GQ. Policy: Global standards for stem-cell research. Nature. 2016 05 19; 533(7603):311-3. PMID: 27193661.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    90. Kimmelman J, Heslop HE, Sugarman J, Studer L, Benvenisty N, Caulfield T, Hyun I, Murry CE, Sipp D, Daley GQ. New ISSCR guidelines: clinical translation of stem cell research. Lancet. 2016 May 14; 387(10032):1979-81. PMID: 27179752.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    91. Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, Murry CE, Piantadosi S, Rao M, Rooke HM, Sipp D, Studer L, Sugarman J, Takahashi M, Zimmerman M, Kimmelman J. Setting Global Standards for Stem Cell Research and Clinical Translation: The?2016 ISSCR Guidelines. Stem Cell Reports. 2016 06 14; 6(6):787-797. PMID: 27185282; PMCID: PMC4912385.
      Citations: 67     Fields:    Translation:HumansCells
    92. Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1. PMID: 26920464; PMCID: PMC4860050.
      Citations: 38     Fields:    Translation:HumansCells
    93. Zhou X, Naik S, Dakhova O, Dotti G, Heslop HE, Brenner MK. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31. PMID: 26708005; PMCID: PMC4886936.
      Citations: 20     Fields:    Translation:HumansCells
    94. Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45. PMID: 26639404; PMCID: PMC4886929.
      Citations: 7     Fields:    Translation:HumansCells
    95. Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83. PMID: 26332003; PMCID: PMC4732525.
      Citations: 56     Fields:    Translation:HumansCells
    96. Manzo T, Heslop HE, Rooney CM. Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015 Oct 15; 24(R1):R67-73. PMID: 26160910; PMCID: PMC4572005.
      Citations: 17     Fields:    Translation:HumansCells
    97. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13. PMID: 25977584; PMCID: PMC4481597.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    98. Naik S, Heslop HE. Engineering haploidentical transplants. Bone Marrow Transplant. 2015 Jul; 50(7):884-5. PMID: 25961777.
      Citations:    Fields:    Translation:Humans
    99. Cohen JI, Niemela JE, Stoddard JL, Pittaluga S, Heslop H, Jaffe ES, Dowdell K. Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1). J Clin Immunol. 2015 Jul; 35(5):445-8. PMID: 25947952; PMCID: PMC4504756.
      Citations: 14     Fields:    Translation:HumansCells
    100. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16. PMID: 25940712; PMCID: PMC4473118.
      Citations: 125     Fields:    Translation:HumansAnimalsCells
    101. Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM. CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63. PMID: 25925682; PMCID: PMC4479400.
      Citations: 43     Fields:    Translation:HumansCells
    102. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96. PMID: 25800760; PMCID: PMC4429176.
      Citations: 373     Fields:    Translation:HumansCellsCTClinical Trials
    103. Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, Gottschalk S, Brenner M, Heslop H, Krance R. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72. PMID: 25765555.
      Citations: 10     Fields:    Translation:Humans
    104. Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, Savoldo B. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest. 2015 Jan; 125(1):157-68. PMID: 25415440; PMCID: PMC4382259.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    105. Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014 Nov; 21(6):476-81. PMID: 25159713; PMCID: PMC4257464.
      Citations: 14     Fields:    Translation:HumansCells
    106. Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24. PMID: 25445636; PMCID: PMC4426907.
      Citations: 12     Fields:    Translation:Humans
    107. Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83. PMID: 25266309; PMCID: PMC4426803.
      Citations: 15     Fields:    Translation:HumansCells
    108. Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, Powell D, Ribas A, Rosenberg S, Sadelain M, Till B, Patterson AP, Jambou RC, Rosenthal E, Gargiulo L, Montgomery M, Kohn DB. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74. PMID: 25186558; PMCID: PMC4435492.
      Citations: 30     Fields:    Translation:HumansCells
    109. Bollard CM, Heslop HE, Rooney CM. Reply to S. Yuan et al. J Clin Oncol. 2014 Sep 01; 32(25):2820-1. PMID: 25049328; PMCID: PMC4145187.
      Citations:    Fields:    Translation:HumansCells
    110. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83. PMID: 24964991; PMCID: PMC4181611.
      Citations: 158     Fields:    Translation:HumansCellsCTClinical Trials
    111. Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF. Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev. 2014; 1:14015. PMID: 26015959; PMCID: PMC4362380.
      Citations: 29     
    112. Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM, Ngo MC. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203. PMID: 24714353; PMCID: PMC4133102.
      Citations: 28     Fields:    Translation:HumansCells
    113. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9. PMID: 24782509; PMCID: PMC4055922.
      Citations: 263     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    114. Kamble RT, Scholoff A, Obi AG, Heslop HE, Brenner MK, Carrum G. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone Marrow Transplant. 2014 Jul; 49(7):986-7. PMID: 24777189.
      Citations:    Fields:    Translation:Humans
    115. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905. PMID: 24753538; PMCID: PMC4064331.
      Citations: 86     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    116. Hildebrandt M, Peggs K, Bollard CM, Heslop HE, Uharek L. Immunotherapy: opportunities, risks and future perspectives. Cytotherapy. 2014 Apr; 16(4 Suppl):S120-9. PMID: 24629797; PMCID: PMC4108615.
      Citations: 4     Fields:    Translation:Humans
    117. Papadopoulou A, Krance RA, Allen CE, Lee D, Rooney CM, Brenner MK, Leen AM, Heslop HE. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138. PMID: 24651135; PMCID: PMC4048900.
      Citations: 15     Fields:    Translation:HumansCells
    118. Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220. PMID: 24732709; PMCID: PMC4048899.
      Citations: 82     Fields:    Translation:HumansAnimalsCells
    119. Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29. PMID: 24517423; PMCID: PMC3927231.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    120. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25. PMID: 24573552; PMCID: PMC3989436.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    121. Rooney CM, Leen AM, Vera JF, Heslop HE. T lymphocytes targeting native receptors. Immunol Rev. 2014 Jan; 257(1):39-55. PMID: 24329788; PMCID: PMC3869095.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    122. Heslop HE. Combining drugs and biologics to treat nasopharyngeal cancer. Mol Ther. 2014 Jan; 22(1):8-9. PMID: 24384910; PMCID: PMC3978800.
      Citations: 3     Fields:    Translation:Humans
    123. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808. PMID: 24344220; PMCID: PMC3940538.
      Citations: 208     Fields:    Translation:HumansCellsCTClinical Trials
    124. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633. PMID: 24213558; PMCID: PMC3945803.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    125. Cox JE, Campos S, Wu J, May R, Liu H, Ramos CA, Carrum G, Heslop HE, Brenner MK, Kamble RT. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22. PMID: 24096822; PMCID: PMC3915247.
      Citations: 4     Fields:    Translation:Humans
    126. Cruz CR, Lam S, Hanley PJ, Bear AS, Langston C, Cohen AJ, Liu H, Martinez CA, Krance RA, Heslop HE, Rooney CM, Hanson IC, Bollard CM. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96. PMID: 23763437; PMCID: PMC3784216.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    127. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73. PMID: 24030379; PMCID: PMC3811171.
      Citations: 231     Fields:    Translation:HumansCellsCTClinical Trials
    128. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Gottachalk S, Yvon E, Ahmed N. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101. PMID: 23939024; PMCID: PMC3831041.
      Citations: 163     Fields:    Translation:HumansAnimalsCells
    129. Heslop HE. Genetic engineering of T-cell receptors: TCR takes to titin. Blood. 2013 Aug 08; 122(6):853-4. PMID: 23929832; PMCID: PMC3739034.
      Citations: 1     Fields:    Translation:HumansCells
    130. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N, Sch?nfeld K. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013 Jul 09; 2:e105. PMID: 23839099; PMCID: PMC3731887.
      Citations: 200     
    131. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21. PMID: 23783429; PMCID: PMC3831033.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    132. Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G, Savoldo B. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013 Sep; 20(9):958-62. PMID: 23698740; PMCID: PMC3766470.
      Citations: 20     Fields:    Translation:HumansCells
    133. Heslop HE. Pharmacotherapy versus T lymphocytes for CMV. Blood. 2013 May 02; 121(18):3544-5. PMID: 23640995; PMCID: PMC3643755.
      Citations: 2     Fields:    Translation:HumansCells
    134. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23. PMID: 23610374; PMCID: PMC3695359.
      Citations: 209     Fields:    Translation:HumansCells
    135. Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013 Feb 15; 95(3):519-26. PMID: 23222884; PMCID: PMC3566275.
      Citations: 5     Fields:    Translation:HumansCells
    136. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76. PMID: 23211628; PMCID: PMC3521877.
      Citations: 34     Fields:    Translation:HumansCells
    137. Heslop HE, Leen AM. T-cell therapy for viral infections. Hematology Am Soc Hematol Educ Program. 2013; 2013:342-7. PMID: 24319202.
      Citations: 15     Fields:    Translation:HumansCells
    138. Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, Savoldo B, Dotti G. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7. PMID: 23242592; PMCID: PMC3659983.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    139. Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18. PMID: 23152545; PMCID: PMC3709638.
      Citations: 41     Fields:    Translation:HumansCells
    140. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013 Jan 01; 19(1):106-17. PMID: 23149818; PMCID: PMC3693218.
      Citations: 40     Fields:    Translation:HumansCells
    141. Fernandez Vina M, Heslop HE, Barker JN. New approaches in alternative donor transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S91-6. PMID: 23110984.
      Citations: 1     Fields:    Translation:Humans
    142. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32. PMID: 22801446; PMCID: PMC3412490.
      Citations: 107     Fields:    Translation:HumansCells
    143. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9. PMID: 22801669; PMCID: PMC3743122.
      Citations: 91     Fields:    Translation:HumansCells
    144. Heslop HE. Equal-opportunity treatment of EBV-PTLD. Blood. 2012 Mar 15; 119(11):2436-8. PMID: 22422813.
      Citations: 1     Fields:    
    145. Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012 Feb; 20(2):246-9. PMID: 22297819; PMCID: PMC3277217.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    146. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68. PMID: 22306904; PMCID: PMC3280423.
      Citations: 35     Fields:    Translation:HumansCells
    147. Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11. PMID: 22172091; PMCID: PMC3705934.
      Citations: 22     Fields:    Translation:HumansCells
    148. Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, Leung KS, Kennedy-Nasser A, Brenner MK, Heslop HE, Liu H, Wu MF, Hanson IC, Krance RA. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83. PMID: 22078471; PMCID: PMC6173521.
      Citations: 26     Fields:    Translation:Humans
    149. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83. PMID: 22047558; PMCID: PMC3236370.
      Citations: 654     Fields:    Translation:HumansCellsCTClinical Trials
    150. Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H, Sacchi N. Definitions of histocompatibility typing terms. Blood. 2011 Dec 01; 118(23):e180-3. PMID: 22001389.
      Citations: 25     Fields:    Translation:Humans
    151. Shaffer DR, Sheehan AM, Yi Z, Rodgers CC, Bollard CM, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61. PMID: 21994111; PMCID: PMC3258475.
      Citations: 1     Fields:    Translation:HumansCells
    152. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6. PMID: 21984804; PMCID: PMC3234664.
      Citations: 490     Fields:    Translation:HumansCellsCTClinical Trials
    153. Heslop HE. TCR expression; quantitative easing by CD3. Blood. 2011 Sep 29; 118(13):3452-3. PMID: 21960676.
      Citations:    Fields:    
    154. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68. PMID: 21915103; PMCID: PMC3242656.
      Citations: 39     Fields:    Translation:HumansCells
    155. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66. PMID: 21908573; PMCID: PMC3218253.
      Citations: 33     Fields:    Translation:HumansCells
    156. Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011 Oct; 13(9):1128-39. PMID: 21745159; PMCID: PMC3687103.
      Citations: 8     Fields:    Translation:HumansCells
    157. Heslop H. Getting personal with melanoma. Clin Cancer Res. 2011 Jul 01; 17(13):4189-91. PMID: 21712453; PMCID: PMC3131472.
      Citations: 1     Fields:    Translation:HumansCells
    158. Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H, Sacchi N, Harmonization of Histocompatibility Typing Terms Working Group. Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. Hum Immunol. 2011 Dec; 72(12):1214-6. PMID: 21723898.
      Citations: 9     Fields:    Translation:HumansCells
    159. Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011 Jun; 16(3):274-80. PMID: 21467936; PMCID: PMC3167800.
      Citations: 19     Fields:    Translation:Humans
    160. Salsman VS, Chow KK, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One. 2011; 6(5):e20267. PMID: 21647415; PMCID: PMC3103535.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    161. Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86. PMID: 21539497; PMCID: PMC3692015.
      Citations: 24     Fields:    Translation:HumansCells
    162. Heslop HE. A less sour sweet; blocking galectin. Blood. 2011 Apr 21; 117(16):4165-6. PMID: 21511962.
      Citations: 1     Fields:    
    163. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6. PMID: 21540550; PMCID: PMC3083795.
      Citations: 473     Fields:    Translation:HumansCells
    164. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49. PMID: 21454450; PMCID: PMC3112034.
      Citations: 100     Fields:    Translation:HumansCells
    165. Ngo MC, Rooney CM, Howard JM, Heslop HE. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 Apr 15; 20(R1):R93-9. PMID: 21415041; PMCID: PMC3095061.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    166. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic. Mol Ther. 2011 Mar; 19(3):432-8. PMID: 21358705; PMCID: PMC3048197.
      Citations: 62     Fields:    Translation:Humans
    167. Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011 Apr; 153(1):76-82. PMID: 21323890; PMCID: PMC3236079.
      Citations: 22     Fields:    Translation:Humans
    168. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62. PMID: 21278353; PMCID: PMC3069675.
      Citations: 42     Fields:    Translation:HumansCells
    169. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Heslop HE, Brenner MK, Krance RA. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51. PMID: 21108446.
      Citations: 4     Fields:    Translation:Humans
    170. Bonini C, Brenner MK, Heslop HE, Morgan RA. Genetic modification of T cells. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S15-20. PMID: 21195304; PMCID: PMC3053011.
      Citations: 19     Fields:    Translation:HumansCells
    171. Horwitz EM, Horowitz MM, DiFronzo NL, Kohn DB, Heslop HE, Blood and Marrow Transplant Clinical Trials Network, State of the Science Cell and Gene Therapy Comm. Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2011 Feb; 17(2):192-6. PMID: 21182973; PMCID: PMC3387575.
      Citations: 1     Fields:    Translation:Humans
    172. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90. PMID: 20948438; PMCID: PMC2964409.
      Citations: 86     Fields:    Translation:HumansCellsCTClinical Trials
    173. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9. PMID: 20429793; PMCID: PMC2914831.
      Citations: 34     Fields:    Translation:Cells
    174. Melenhorst JJ, Leen AM, Bollard CM, Price DA, Rooney CM, Brenner MK, Barrett AJ, Heslop HE, Quigley MF. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2. PMID: 20709906; PMCID: PMC2996125.
      Citations: 76     Fields:    Translation:HumansCells
    175. Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15. PMID: 20506146; PMCID: PMC3290395.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    176. Shafer JA, Cruz CR, Leen AM, Ku S, Lu A, Rousseau A, Heslop HE, Rooney CM, Bollard CM, Foster AE. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010 May; 51(5):870-80. PMID: 20367572; PMCID: PMC2991134.
      Citations: 20     Fields:    Translation:HumansCells
    177. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70. PMID: 20428207; PMCID: PMC2888148.
      Citations: 243     Fields:    Translation:HumansAnimalsCells
    178. Shafer JA, Heslop HE, Brenner MK, Carrum G, Wu MF, Liu H, Ahmed N, Gottschalk S, Kamble R, Leung KS, Myers GD, Bollard CM, Krance RA. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70. PMID: 20367182; PMCID: PMC2932472.
      Citations: 8     Fields:    Translation:Humans
    179. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, Rooney CM. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010 Apr; 33(3):305-15. PMID: 20445351; PMCID: PMC2946348.
      Citations: 76     Fields:    Translation:HumansCells
    180. Heslop HE. Safer CARS. Mol Ther. 2010 Apr; 18(4):661-2. PMID: 20357776; PMCID: PMC2862533.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    181. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Gottschalk SM, Bollard CM, Heslop HE, Brenner MK, Krance RA. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81. PMID: 20348004; PMCID: PMC2919628.
      Citations: 18     Fields:    Translation:Humans
    182. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7. PMID: 20171074; PMCID: PMC3093371.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    183. Schriber JR, Anasetti C, Heslop HE, Leahigh AK. Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. Biol Blood Marrow Transplant. 2010 May; 16(5):595-7. PMID: 20167277.
      Citations: 7     Fields:    Translation:Humans
    184. Ahmed N, Heslop HE, Mackall CL. T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am. 2010 Feb; 57(1):83-96. PMID: 20307713; PMCID: PMC2844874.
      Citations: 3     Fields:    Translation:HumansCells
    185. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703. PMID: 20110422; PMCID: PMC2852368.
      Citations: 47     Fields:    Translation:HumansCells
    186. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010 Mar; 24(3):563-72. PMID: 20072155; PMCID: PMC2836398.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    187. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15; 16(2):474-85. PMID: 20068073; PMCID: PMC3682507.
      Citations: 174     Fields:    Translation:HumansAnimalsCells
    188. Gao X, Xue Z, Xing J, Lee DY, Gottschalk SM, Heslop HE, Bollard CM, Wong ST. Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. Acad Radiol. 2010 Apr; 17(4):479-88. PMID: 20060747; PMCID: PMC2846835.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    189. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009 Nov 18; 8:106. PMID: 19922650; PMCID: PMC2784756.
      Citations: 3     Fields:    Translation:HumansCells
    190. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35. PMID: 19880495; PMCID: PMC2817637.
      Citations: 331     Fields:    Translation:HumansCellsCTClinical Trials
    191. Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1493-501. PMID: 19781658.
      Citations: 10     Fields:    Translation:Humans
    192. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91. PMID: 19759356; PMCID: PMC2786289.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    193. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009 Nov 05; 114(19):4002-8. PMID: 19724053; PMCID: PMC2774540.
      Citations: 102     Fields:    Translation:HumansCells
    194. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92. PMID: 19700662; PMCID: PMC2774556.
      Citations: 143     Fields:    Translation:HumansCellsCTClinical Trials
    195. Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25. PMID: 19584818; PMCID: PMC2835253.
      Citations: 37     Fields:    Translation:HumansCells
    196. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87. PMID: 19532139; PMCID: PMC2835000.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    197. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67. PMID: 19443656; PMCID: PMC2738578.
      Citations: 98     Fields:    Translation:HumansCells
    198. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402. PMID: 19377047; PMCID: PMC2710932.
      Citations: 237     Fields:    Translation:HumansAnimalsCells
    199. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8. PMID: 19259067; PMCID: PMC2835146.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    200. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70. PMID: 18978797; PMCID: PMC2749734.
      Citations: 579     Fields:    Translation:HumansCells
    201. Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304. PMID: 18940685.
      Citations: 7     Fields:    Translation:Humans
    202. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52. PMID: 18940679.
      Citations: 26     Fields:    Translation:HumansCells
    203. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50. PMID: 18971421; PMCID: PMC2656271.
      Citations: 58     Fields:    Translation:HumansCellsCTClinical Trials
    204. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008 Oct 21; 71(17):1326-34. PMID: 18936424.
      Citations: 43     Fields:    Translation:Humans
    205. Heslop HE, Brenner MK. The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1. PMID: 18725876.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    206. Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008 Sep; 21(3):405-20. PMID: 18790446; PMCID: PMC2610025.
      Citations: 10     Fields:    Translation:HumansCells
    207. Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74. PMID: 18600178; PMCID: PMC2643068.
      Citations: 11     Fields:    Translation:HumansCells
    208. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol. 2008 Oct; 143(2):169-79. PMID: 18691164; PMCID: PMC3153888.
      Citations: 13     Fields:    Translation:HumansCells
    209. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008 Sep 01; 112(5):1876-85. PMID: 18591381; PMCID: PMC3401035.
      Citations: 50     Fields:    Translation:HumansCells
    210. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5. PMID: 18463534; PMCID: PMC2745436.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    211. Craddock J, Heslop HE. Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens. Update Cancer Ther. 2008 Mar; 3(1):33-41. PMID: 19255606; PMCID: PMC2390887.
      Citations: 8     
    212. Pule MA, Rousseau A, Vera J, Heslop HE, Brenner MK, Vanin EF. Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. Cytotherapy. 2008; 10(5):526-39. PMID: 18821360; PMCID: PMC2749733.
      Citations: 7     Fields:    Translation:HumansCells
    213. Falkenburg JH, Heslop HE, Barrett AJ. T cell therapy in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):136-41. PMID: 18162234; PMCID: PMC3426445.
      Citations: 4     Fields:    Translation:HumansCells
    214. Cairo MS, Heslop H. Pediatric blood and marrow transplantation: state of the science. Bone Marrow Transplant. 2008 Jan; 41(2):97. PMID: 18231112.
      Citations: 5     Fields:    Translation:Humans
    215. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 2008 Jan; 41(2):193-8. PMID: 17982497.
      Citations: 30     Fields:    Translation:HumansCells
    216. Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1268-85. PMID: 17950914.
      Citations: 13     Fields:    Translation:Humans
    217. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54. PMID: 17942545; PMCID: PMC2224388.
      Citations: 71     Fields:    Translation:HumansCells
    218. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802. PMID: 17638856; PMCID: PMC2018664.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    219. Kamble RT, Clark DA, Leong HN, Heslop HE, Brenner MK, Carrum G. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6. PMID: 17637686.
      Citations: 14     Fields:    Translation:HumansCells
    220. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45. PMID: 17609424; PMCID: PMC2018666.
      Citations: 157     Fields:    Translation:HumansCellsCTClinical Trials
    221. Louis CU, Paulino AC, Gottschalk S, Bertuch AA, Chintagumpala M, Heslop HE, Russell HV. A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5. PMID: 17609631.
      Citations: 7     Fields:    Translation:Humans
    222. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64. PMID: 17575166.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    223. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24. PMID: 17640595; PMCID: PMC2040267.
      Citations: 104     Fields:    Translation:HumansCells
    224. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30. PMID: 17507664; PMCID: PMC1988944.
      Citations: 114     Fields:    Translation:HumansAnimalsCells
    225. Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE, Leen AM. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86. PMID: 17417664.
      Citations: 16     Fields:    Translation:HumansCells
    226. Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9. PMID: 17401392.
      Citations: 20     Fields:    Translation:HumansCells
    227. Heslop HE. Gene therapy. Cytotherapy. 2007; 9(6):519-20. PMID: 17882715.
      Citations:    Fields:    Translation:Humans
    228. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84. PMID: 17162209.
      Citations: 29     Fields:    Translation:HumansCells
    229. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007 Mar 15; 109(6):2657-62. PMID: 17110457.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    230. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, Gee AP, Scott JD, Savoldo B. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94. PMID: 17100717.
      Citations: 9     Fields:    Translation:HumansCells
    231. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6. PMID: 16998485.
      Citations: 254     Fields:    Translation:HumansCells
    232. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, Dotti G. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7. PMID: 16926291; PMCID: PMC1895462.
      Citations: 152     Fields:    Translation:HumansAnimalsCells
    233. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9. PMID: 16835376; PMCID: PMC1895521.
      Citations: 84     Fields:    Translation:HumansCells
    234. Ahmed N, Heslop HE. Viral lymphomagenesis. Curr Opin Hematol. 2006 Jul; 13(4):254-9. PMID: 16755222.
      Citations: 2     Fields:    Translation:HumansCells
    235. Heslop HE. Commentary on journal of immunotherapy paper by melenhorst et al. J Immunother. 2006 Jul-Aug; 29(4):365-6. PMID: 16799331.
      Citations:    Fields:    Translation:HumansCells
    236. Tey SK, Bollard CM, Heslop HE. Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol. 2006 Jun; 84(3):281-9. PMID: 16681825.
      Citations: 17     Fields:    Translation:HumansCells
    237. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808. PMID: 16741253; PMCID: PMC1895537.
      Citations: 81     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    238. Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93. PMID: 16824159.
      Citations: 16     Fields:    Translation:HumansCells
    239. Jones RB, Anasetti C, Appel P, DiPersio J, Heslop H, Lemaistre F, Silver S, Sirilla J, Stiff P, Committee on Hematopoietic Cell Therapy Quality Outcomes. ASBMT committee report: white paper on measurement of quality outcomes. Biol Blood Marrow Transplant. 2006 May; 12(5):594-7. PMID: 16635795.
      Citations: 1     Fields:    Translation:Humans
    240. Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, Finegold M, Weiss H, Chen SY, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60. PMID: 16699368.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    241. Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42. PMID: 16753867.
      Citations: 11     Fields:    Translation:HumansCells
    242. Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52. PMID: 16462757.
      Citations: 6     Fields:    Translation:Humans
    243. Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7. PMID: 16507214.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    244. Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82. PMID: 17824182.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    245. Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, Gee AP, Heslop HE, Rooney CM. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15. PMID: 16461793.
      Citations: 12     Fields:    Translation:HumansCells
    246. Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, Bollard CM. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005 Dec; 36(11):1001-8. PMID: 16184180.
      Citations: 33     Fields:    Translation:Humans
    247. Hale GA, Bowman LC, Rochester RJ, Benaim E, Heslop HE, Krance RA, Horwitz EM, Cunningham JM, Tong X, Srivastava DK, Handgretinger R, Jones DP. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant. 2005 Nov; 11(11):912-20. PMID: 16275594.
      Citations: 18     Fields:    Translation:HumansCells
    248. Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802. PMID: 16151431.
      Citations: 12     Fields:    Translation:HumansCells
    249. Biagi E, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK, Rousseau RF, Dutour A. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41. PMID: 16249392; PMCID: PMC1895421.
      Citations: 24     Fields:    Translation:HumansCells
    250. Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15; 175(6):4137-47. PMID: 16148164.
      Citations: 33     Fields:    Translation:HumansCells
    251. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8. PMID: 16095501.
      Citations: 42     Fields:    Translation:HumansCells
    252. Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK, Pul? MA. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41. PMID: 15979412.
      Citations: 223     Fields:    Translation:HumansCells
    253. Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32. PMID: 15834432.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    254. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005 Mar; 5(3):566-72. PMID: 15707412.
      Citations: 26     Fields:    Translation:HumansCells
    255. Straathof KC, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM, Pul? MA. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54. PMID: 15728125; PMCID: PMC1895037.
      Citations: 297     Fields:    Translation:HumansAnimalsCells
    256. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56:29-44. PMID: 15660500.
      Citations: 132     Fields:    Translation:HumansCells
    257. Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005; 260-6. PMID: 16304390.
      Citations: 44     Fields:    Translation:HumansCells
    258. Dotti G, Heslop HE. Current status of genetic modification of T cells for cancer treatment. Cytotherapy. 2005; 7(3):262-72. PMID: 16081353.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    259. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005 Jan; 46(1):1-10. PMID: 15621775.
      Citations: 43     Fields:    Translation:Humans
    260. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33. PMID: 15611290; PMCID: PMC2211993.
      Citations: 131     Fields:    Translation:HumansCells
    261. Yotnda P, Zompeta C, Heslop HE, Andreeff M, Brenner MK, Marini F. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42. PMID: 15684699.
      Citations: 12     Fields:    Translation:HumansCells
    262. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 01; 105(5):1898-904. PMID: 15542583.
      Citations: 128     Fields:    Translation:HumansCellsCTClinical Trials
    263. Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7. PMID: 15371682.
      Citations: 10     Fields:    Translation:HumansCells
    264. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004 Sep; 17(3):401-13. PMID: 15498712.
      Citations: 5     Fields:    Translation:HumansCells
    265. Heslop HE, Gottschalk SM, Bollard CM, Straathof KC, Huls MH, Brenner MK, Rooney CM. Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4. PMID: 15209923.
      Citations:    Fields:    Translation:HumansCells
    266. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27. PMID: 15235393.
      Citations: 35     Fields:    Translation:HumansCells
    267. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55. PMID: 14993880.
      Citations: 32     Fields:    Translation:HumansCells
    268. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008. PMID: 14985264.
      Citations: 28     Fields:    Translation:HumansCells
    269. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004 Feb 16; 199(4):459-70. PMID: 14769850; PMCID: PMC2211826.
      Citations: 62     Fields:    Translation:HumansCells
    270. Wagner HJ, Bollard CM, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM, Vigouroux S. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91. PMID: 14685154.
      Citations: 33     Fields:    Translation:HumansCells
    271. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81. PMID: 14751931.
      Citations: 48     Fields:    Translation:HumansCells
    272. Ganguly S, Carrum G, Nizzi F, Heslop HE, Popat U. Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. Am J Hematol. 2004 Jan; 75(1):48-51. PMID: 14695632.
      Citations: 5     Fields:    Translation:HumansCells
    273. Hale GA, Rochester RJ, Heslop HE, Krance RA, Gingrich JR, Benaim E, Horwitz EM, Cunningham JM, Tong X, Srivastava DK, Leung WH, Woodard P, Bowman LC, Handgretinger R. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant. 2003 Nov; 9(11):698-705. PMID: 14652853.
      Citations: 13     Fields:    Translation:Humans
    274. Hale GA, Bowman LC, Woodard JP, Cunningham JM, Benaim E, Horwitz EM, Heslop HE, Krance RA, Leung W, Shearer PD, Handgretinger R. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant. 2003 Jun; 31(11):981-6. PMID: 12774048.
      Citations: 1     Fields:    Translation:HumansCells
    275. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9. PMID: 12763937.
      Citations: 40     Fields:    Translation:HumansCells
    276. Brenner MK, Wulf GG, Rill DR, Luo KL, Goodell MA, Mei Z, Kuehnle I, Brown MP, Pule M, Heslop HE, Krance RA. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8. PMID: 12799286.
      Citations: 9     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    277. Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56. PMID: 12806278.
      Citations: 23     Fields:    Translation:HumansCells
    278. Krance RA, Kuehnle I, Rill DR, Mei Z, Pinetta C, Evans W, Brown MP, Heslop HE, Brenner MK, Pul? M. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81. PMID: 12720220.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    279. Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev. 2003 Feb; 29(1):3-10. PMID: 12633575.
      Citations: 3     Fields:    Translation:Humans
    280. Wagner HJ, Sili U, Gahn B, Vigouroux S, Huls MH, Xie W, Vignali D, Brenner MK, Heslop HE, Rooney CM. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40. PMID: 12850791.
      Citations: 3     Fields:    Translation:HumansCells
    281. Brenner MK, Heslop HE. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3. PMID: 12850996.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    282. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program. 2003; 331-49. PMID: 14633789.
      Citations: 18     Fields:    Translation:HumansCells
    283. Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48. PMID: 14583674.
      Citations: 11     Fields:    Translation:HumansCells
    284. Huls MH, Rooney CM, Heslop HE. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol. 2003; 110(2-3):149-53. PMID: 14583675.
      Citations:    Fields:    Translation:HumansCells
    285. Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98. PMID: 12604735.
      Citations: 7     Fields:    Translation:HumansCells
    286. Voo KS, Fu T, Heslop HE, Brenner MK, Rooney CM, Wang RF. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9. PMID: 12499257.
      Citations: 23     Fields:    Translation:HumansCells
    287. Carter BA, Karpen SJ, Quiros-Tejeira RE, Chang IF, Clark BS, Demmler GJ, Heslop HE, Scott JD, Seu P, Goss JA. Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 Oct 15; 74(7):1050-2. PMID: 12394854.
      Citations: 10     Fields:    Translation:HumansCells
    288. Ringwald-Smith KA, Heslop HE, Krance RA, Mackert PW, Hancock ML, Stricklin LM, Bowman LC, Hale GA. Energy expenditure in children undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 Jul; 30(2):125-30. PMID: 12132052.
      Citations: 7     Fields:    Translation:Humans
    289. Rousseau R, Bollard C, Heslop H. [Contribution of antineoplastic biotherapy in the treatment of leukemia in children]. Arch Pediatr. 2002 Mar; 9(3):289-306. PMID: 11938542.
      Citations:    Fields:    Translation:HumansCells
    290. Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, Rooney CM. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18. PMID: 11777989.
      Citations: 27     Fields:    Translation:HumansCells
    291. Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4. PMID: 12473214.
      Citations: 4     Fields:    Translation:HumansCells
    292. Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42. PMID: 12611071.
      Citations: 8     Fields:    Translation:HumansCells
    293. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33. PMID: 11785836.
      Citations: 19     Fields:    Translation:HumansCells
    294. Gahn B, Hunt G, Rooney CM, Heslop HE. Immunotherapy to reconstitute immunity to DNA viruses. Semin Hematol. 2002 Jan; 39(1):41-7. PMID: 11799528.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    295. Gottschalk S, Heslop HE, Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002; 84:175-201. PMID: 11883527.
      Citations: 6     Fields:    Translation:HumansCells
    296. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 01; 98(7):2052-8. PMID: 11567989.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    297. Heslop HE. Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation. J Immunother. 2001 Jul-Aug; 24(4):283-4. PMID: 11565828.
      Citations:    Fields:    Translation:HumansCells
    298. Rousseau RF, Bollard CM, Heslop HE. Gene therapy for paediatric leukaemia. Expert Opin Biol Ther. 2001 Jul; 1(4):663-74. PMID: 11727502.
      Citations: 1     Fields:    Translation:HumansCells
    299. Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, Davis A. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7. PMID: 11426333.
      Citations: 41     Fields:    Translation:HumansCells
    300. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43. PMID: 11159505.
      Citations: 98     Fields:    Translation:HumansCells
    301. Hale GA, Tong X, Benaim E, Cunningham JM, Heslop HE, Horwiz EM, Leung W, Rochester RJ, Shearer PD, Srivastava DK, Woodard JP, Bowman LC. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplant. 2001 Jan; 27(2):155-62. PMID: 11281384.
      Citations: 1     Fields:    Translation:Humans
    302. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9. PMID: 11443864.
      Citations: 13     Fields:    Translation:HumansCells
    303. Bollard CM, Heslop HE, Brenner MK. Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22. PMID: 11372750.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    304. Savoldo B, Heslop HE, Rooney CM. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma. 2000 Nov; 39(5-6):455-64. PMID: 11342329.
      Citations: 2     Fields:    Translation:HumansCells
    305. Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75. PMID: 10910143.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    306. Brenner MK, Heslop H, Krance R, Horowitz M, Strother D, Nuchtern J, Grilley B, Martingano E, Cooper K. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88. PMID: 10910144.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    307. Heslop HE. Gene therapy of pediatric leukemia. Clin Lab Med. 2000 Mar; 20(1):183-95, x. PMID: 10702902.
      Citations:    Fields:    Translation:HumansCells
    308. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5. PMID: 10666232.
      Citations: 40     Fields:    Translation:HumansCells
    309. Hale GA, Heslop HE, Bowman LC, Rochester RA, Pui CH, Brenner MK, Krance RA. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999 Oct; 24(7):735-9. PMID: 10516676.
      Citations: 9     Fields:    Translation:Humans
    310. Heslop HE. Haemopoietic stem cell transplantation from unrelated donors. Br J Haematol. 1999 Apr; 105(1):2-6. PMID: 10366243.
      Citations:    Fields:    Translation:Humans
    311. Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999 Mar; 11(2):96-101. PMID: 10188073.
      Citations: 5     Fields:    Translation:HumansCells
    312. Hale GA, Heslop HE, Krance RA, Brenner MA, Jayawardene D, Srivastava DK, Patrick CC. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 Feb; 23(3):277-82. PMID: 10084260.
      Citations: 44     Fields:    Translation:Humans
    313. Heslop HE, Perez M, Benaim E, Rochester R, Brenner MK, Rooney CM. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999; 14(3):154-6. PMID: 10540372.
      Citations: 5     Fields:    Translation:HumansCells
    314. Moriwaki K, Sutton RE, Perez M, Brenner MK, Heslop HE. Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. Cytotherapy. 1999; 1(6):433-8. PMID: 20426543.
      Citations:    Fields:    Translation:HumansCells
    315. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55. PMID: 9716582.
      Citations: 270     Fields:    Translation:HumansCells
    316. Fletcher BD, Heslop HE, Kaste SC, Bodner S. Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. Pediatr Radiol. 1998 Jul; 28(7):492-6. PMID: 9662565.
      Citations:    Fields:    Translation:HumansCells
    317. Hutchings M, Moriwaki K, Dilloo D, Hoffmann T, Kimbrough S, Johnsen HE, Brenner MK, Heslop HE. Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J Hematother. 1998 Jun; 7(3):217-24. PMID: 9621255.
      Citations: 2     Fields:    Translation:HumansCells
    318. Roskrow MA, Rooney CM, Heslop HE, Brenner MK, Krance RA, Gresik MV, McClain K, Aguilar LK, Grilley B, Rob E, Carrum G. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50. PMID: 9625264.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    319. Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998 Apr 15; 91(8):2925-34. PMID: 9531603.
      Citations: 68     Fields:    Translation:HumansCellsCTClinical Trials
    320. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93. PMID: 9709309.
      Citations: 9     Fields:    Translation:HumansCells
    321. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32. PMID: 9926252.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    322. Brenner MK, Heslop HE, Rooney CM. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90. PMID: 9704428.
      Citations:    Fields:    Translation:HumansCells
    323. Rooney CM, Heslop HE, Brenner MK. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8. PMID: 9704488.
      Citations: 5     Fields:    Translation:HumansCells
    324. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38. PMID: 9449381.
      Citations: 4     Fields:    Translation:Humans
    325. Kauffman WM, Heslop HE, Gronemeyer SA, Chen G, Krance RA. Hepatic arterial resistance index--an indicator of diffuse liver disease in children treated with bone marrow transplantation. Clin Radiol. 1997 Dec; 52(12):903-6. PMID: 9413962.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    326. Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horwitz EM, Brenner MK, Heslop HE. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997 Sep 13; 350(9080):767-71. PMID: 9297996.
      Citations: 14     Fields:    Translation:Humans
    327. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997 Jun; 157:217-22. PMID: 9255632.
      Citations: 37     Fields:    Translation:HumansCells
    328. Rooney CM, Smith CA, Heslop HE. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today. 1997 Jan; 3(1):24-30. PMID: 9021739.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    329. Comoli P, Dilloo D, Hutchings M, Hoffma T, Heslop HE. Measuring gene-transfer efficiency. Nat Med. 1996 Dec; 2(12):1280-1. PMID: 8946816.
      Citations:    Fields:    Translation:HumansCells
    330. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Tiberghien P, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313. PMID: 8953320.
      Citations: 1     Fields:    Translation:Humans
    331. Smith CA, Ng CY, Loftin SK, Li C, Heslop HE, Brenner MK, Rooney CM. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996 Oct; 23(3-4):213-20. PMID: 9031101.
      Citations: 5     Fields:    Translation:HumansCells
    332. Brenner MK, Heslop HE, Rill D, Li C, Smith C, Krance R, Rooney C. Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200. PMID: 9384704.
      Citations:    Fields:    Translation:HumansCells
    333. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Aebischer P, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47. PMID: 8864763.
      Citations: 1     Fields:    Translation:Humans
    334. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5. PMID: 8616714.
      Citations: 195     Fields:    Translation:HumansCells
    335. Heslop HE, Brenner MK, Krance RA, Bowman L, Cunningham JM, Richardson S, Alexander B, Heideman R, Boyett JM, Srivastava DK, Marcus SG, Berenson R, Heimfeld S, Brown S. Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67. PMID: 8845391.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    336. Cela ME, Holladay MS, Rooney CM, Richardson S, Alexander B, Krance RA, Brenner MK, Heslop HE. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7. PMID: 8640174.
      Citations: 12     Fields:    Translation:HumansCells
    337. Heslop HE, Rooney CM, Rill DR, Krance RA, Brenner MK. Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13. PMID: 8706035.
      Citations: 2     Fields:    Translation:HumansCells
    338. Pui CH, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE, Santana VM, Ribeiro RC, Sandlund JT, Mahmoud HH, et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995 Dec; 9(12):1990-6. PMID: 8609707.
      Citations: 16     Fields:    Translation:Humans
    339. Heslop HE, Rooney CM, Brenner MK. Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5. PMID: 8839397.
      Citations: 1     Fields:    Translation:Humans
    340. Heslop HE, Roskrow M. Gene transfer for the therapy of hematologic malignancy. Curr Opin Hematol. 1995 Nov; 2(6):417-22. PMID: 9372030.
      Citations: 1     Fields:    Translation:HumansCells
    341. Kauffman WM, Zuckerman SL, Heslop HE, Krance RA. Portal venous Doppler findings in a bone marrow transplant patient with cardiac tamponade. J Ultrasound Med. 1995 Nov; 14(11):877-9. PMID: 8551557.
      Citations:    Fields:    Translation:Humans
    342. Heslop HE, Benaim E, Brenner MK, Krance RA, Stricklin LM, Rochester RJ, Billing R. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6. PMID: 7674747.
      Citations: 3     Fields:    Translation:HumansCells
    343. Smith FS, Rencher SD, Heslop HE, Hurwitz JL. T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipient. Cancer Immunol Immunother. 1995 Aug; 41(2):104-10. PMID: 7656269.
      Citations: 2     Fields:    Translation:HumansCells
    344. Phipps S, Brenner M, Heslop H, Krance R, Jayawardene D, Mulhern R. Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. Bone Marrow Transplant. 1995 Jun; 15(6):829-35. PMID: 7581077.
      Citations: 12     Fields:    Translation:Humans
    345. Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9. PMID: 7633844.
      Citations: 42     Fields:    Translation:HumansCells
    346. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13. PMID: 7799740.
      Citations: 256     Fields:    Translation:HumansCells
    347. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103. PMID: 7833284.
      Citations: 25     Fields:    Translation:HumansCells
    348. Brenner MK, Cunningham JM, Sorrentino BP, Heslop HE. Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91. PMID: 7767642.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    349. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 08; 331(10):679-80. PMID: 8052285.
      Citations: 60     Fields:    Translation:HumansCells
    350. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994 Jul 15; 84(2):380-3. PMID: 8025266.
      Citations: 40     Fields:    Translation:HumansCells
    351. Brenner MK, Rill DR, Moen RC, Krance RA, Heslop HE, Mirro J, Anderson WF, Ihle JN. Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci. 1994 May 31; 716:204-14; discussion 214-5, 225-7. PMID: 8024195.
      Citations: 5     Fields:    Translation:HumansCells
    352. Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5. PMID: 7519937.
      Citations: 4     Fields:    Translation:HumansCells
    353. Brenner M, Krance R, Heslop HE, Santana V, Ihle J, Ribeiro R, Roberts WM, Mahmoud H, Boyett J, Moen RC, et al. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99. PMID: 8049305.
      Citations: 2     Fields:    Translation:HumansCells
    354. Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM. Epstein-Barr infection after bone marrow transplantation. Blood. 1994 Mar 15; 83(6):1706-8. PMID: 8123864.
      Citations: 3     Fields:    Translation:HumansCells
    355. Heslop HE. Cytokine gene transfer in the therapy of malignancy. Baillieres Clin Haematol. 1994 Mar; 7(1):135-51. PMID: 8038497.
      Citations:    Fields:    Translation:HumansAnimalsCells
    356. Heslop HE, Brenner MK, Rooney C, Krance RA, Roberts WM, Rochester R, Smith CA, Turner V, Sixbey J, Moen R, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97. PMID: 8018749.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    357. Mathew P, Bozeman P, Krance RA, Brenner MK, Heslop HE. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 Feb; 13(2):221-3. PMID: 8205095.
      Citations: 5     Fields:    Translation:Humans
    358. Brenner MK, Heslop HE, Rill D, Li C, Nilson T, Roberts M, Smith C, Krance R, Rooney C. Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7. PMID: 7587132.
      Citations: 1     Fields:    Translation:HumansCells
    359. Brenner MK, Rill DR, Heslop HE, Rooney CM, Roberts WM, Li C, Nilson T, Krance RA. Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6. PMID: 7654451.
      Citations: 3     Fields:    Translation:HumansCells
    360. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7. PMID: 7901474.
      Citations: 41     Fields:    Translation:Humans
    361. Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8. PMID: 8102723.
      Citations: 6     Fields:    Translation:Humans
    362. Heslop HE, Hoffbrand AV, Brenner MK. TNF and chronic B lymphoproliferative disorders. Leukemia. 1993 Sep; 7(9):1476. PMID: 8371597.
      Citations: 1     Fields:    Translation:Humans
    363. Krance R, Heslop HE, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, Horowitz MM, Brenner MK. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant. 1993 Jan; 11(1):33-6. PMID: 8431709.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    364. Rencher SD, Hanif I, Heslop HE, Turner VE, Brenner MK, Hurwitz JL. Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT. Bone Marrow Transplant. 1992 Dec; 10(6):521-7. PMID: 1490202.
      Citations: 1     Fields:    Translation:HumansCells
    365. Gottlieb DJ, Prentice HG, Heslop HE, Bello C, Brenner MK. IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8. PMID: 1544235; PMCID: PMC1554326.
      Citations: 4     Fields:    Translation:HumansAnimals
    366. Brenner MK, Heslop HE. Immunotherapy of leukemia. Leukemia. 1992; 6 Suppl 1:76-9. PMID: 1548941.
      Citations:    Fields:    Translation:Humans
    367. Brenner MK, Heslop HE. Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7. PMID: 1836732.
      Citations:    Fields:    Translation:HumansAnimalsCells
    368. Heslop HE, Brenner MK, Ganeshaguru K, Hoffbrand AV. Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Br J Haematol. 1991 Oct; 79 Suppl 1:14-6. PMID: 1931702.
      Citations: 1     Fields:    Translation:HumansCells
    369. Brenner MK, Heslop HE. Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol. 1991 Jul; 4(3):727-49. PMID: 1958889.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    370. Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz G, Veys P, Wilkes S, Prentice HG, Hazlehurst G, Hoffbrand AV, et al. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood. 1991 May 01; 77(9):1996-2001. PMID: 1708296.
      Citations: 4     Fields:    Translation:HumansCells
    371. Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol. 1991 Apr; 11(4):1912-20. PMID: 2005887; PMCID: PMC359873.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    372. Bello-Fernandez C, Bird C, Heslop HE, Gottlieb DJ, Reittie JE, Rill DM, Holland M, Prentice HG, Brenner MK. Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function. Blood. 1991 Mar 15; 77(6):1283-9. PMID: 1900445.
      Citations: 1     Fields:    Translation:HumansCells
    373. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol. 1991 Feb; 77(2):237-44. PMID: 2004026.
      Citations: 4     Fields:    Translation:Humans
    374. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand AV, Brenner MK. Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. Transplant Proc. 1991 Feb; 23(1 Pt 2):1704-5. PMID: 1989334.
      Citations: 1     Fields:    Translation:HumansCells
    375. Heslop HE, Bianchi AC, Cordingley FT, Turner M, Chandima W, De Mel CP, Hoffbrand AV, Brenner MK. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990 Dec 01; 172(6):1729-34. PMID: 2258703; PMCID: PMC2188757.
      Citations: 14     Fields:    Translation:HumansCells
    376. Duncombe AS, Meager A, Prentice HG, Grundy JE, Heslop HE, Hoffbrand AV, Brenner MK. Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990 Sep 01; 76(5):1046-53. PMID: 2168224.
      Citations: 4     Fields:    Translation:HumansCells
    377. Gottlieb DJ, Prentice HG, Mehta AB, Galazka AR, Heslop HE, Hoffbrand AV, Brenner MK. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol. 1990 Aug; 75(4):499-505. PMID: 2119792.
      Citations: 4     Fields:    Translation:HumansCells
    378. Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK. Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol. 1990 Jan 15; 144(2):541-7. PMID: 2136894.
      Citations: 9     Fields:    Translation:HumansCells
    379. Browett PJ, Heslop HE, Mehta AB, Norton JD. The t(9;22) translocation in Philadelphia-positive essential thrombocythaemia does not involve the T lymphocyte lineage. Acta Haematol. 1990; 83(4):203-5. PMID: 2142847.
      Citations:    Fields:    Translation:HumansCells
    380. Gignac SM, Buschle M, Heslop HE, Brenner MK, Hoffbrand AV, Drexler HG. Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor. Leuk Lymphoma. 1990; 3(1):37-43. PMID: 27457196.
      Citations:    Fields:    
    381. Duncombe AS, Heslop HE, Turner M, Meager A, Priest R, Exley T, Brenner MK. Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol. 1989 Dec 01; 143(11):3828-34. PMID: 2584719.
      Citations: 9     Fields:    Translation:HumansCells
    382. Bianchi AC, Heslop HE, Veys P, Macey M, Holland M, Prentice HG, Brenner MK. Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol. 1989 Dec; 73(4):468-74. PMID: 2692692.
      Citations:    Fields:    Translation:HumansCells
    383. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42. PMID: 2804369.
      Citations: 11     Fields:    Translation:HumansCells
    384. Gottlieb DJ, Brenner MK, Heslop HE, Bianchi AC, Bello-Fernandez C, Mehta AB, Newland AC, Galazka AR, Scott EM, Hoffbrand AV, et al. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer. 1989 Oct; 60(4):610-5. PMID: 2803933; PMCID: PMC2247111.
      Citations: 13     Fields:    Translation:Humans
    385. Heslop HE, Gottlieb DJ, Bianchi AC, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep; 74(4):1374-80. PMID: 2504308.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    386. Heslop HE, Gottlieb DJ, Reittie JE, Bello-Fernandez C, Meager A, Prentice HG, Brenner MK. Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol. 1989 Jun; 72(2):122-6. PMID: 2503022.
      Citations: 6     Fields:    Translation:HumansCells
    387. Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8. PMID: 2495037.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    388. Heslop HE, Price GM, Prentice HG, Cordingley FT, Webster AD, Hoffbrand AV, Brenner MK. In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. J Immunol. 1988 May 15; 140(10):3461-6. PMID: 3283234.
      Citations: 2     Fields:    Translation:HumansCells
    389. Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30; 1(8592):969-71. PMID: 2896830.
      Citations: 40     Fields:    Translation:HumansCells
    390. Bianchi AC, Heslop HE, Drexler HG, Cordingley FT, Turner M, De Mel WC, Hoffbrand AV, Brenner MK. Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. Nouv Rev Fr Hematol (1978). 1988; 30(5-6):317-9. PMID: 3265501.
      Citations: 1     Fields:    Translation:HumansCells
    391. Heslop HE, Heaton DC, Hart DN, Allen JR, Abbott GD, Beard ME. Allogeneic bone marrow transplantation at Christchurch 1979-1985. N Z Med J. 1986 May 14; 99(801):318-21. PMID: 3520412.
      Citations:    Fields:    Translation:Humans
    HESLOP's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (805)
    Explore
    _
    Co-Authors (120)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _